ExQor's business is developing innovative bio-nanotechnologies. Its multi-patented nano-platform enables a blood brain barrier transporter of large and small molecule CNS drugs that fulfills unmet medical needs such as,
- Early screening for neurodegenerative diseases, including CNS metastases.
- Early diagnosis even when clinical evidence is not typically present.
- Early intervention to prevent disease onset now or later in life.
- Well-tolerated, low dose CNS drug maintenance that makes it easy to stay well.
—The ExQor-Clathrin drug transporter non-invasively passes an intact blood brain barrier (BBB) as found in patients not presenting symptoms, but who are at medical risk for reasons of genetics, trauma, environmental conditions, etc.
— Large and small molecule drug payloads of most any type can be precisely targeted by the ExQor-Clathrin transporter to the brain.
— Highly flexible, low dose therapies with minimal adverse affects, a key consideration in patient compliance, especially for symptom-free individuals.
ExQor Technologies, Inc.
4 Longfellow Place
Suite 2105
Boston MA 02114-2818 USA